Concepedia

Author

Patrizia Racca

Azienda Ospedaliera Citta' della Salute e della Scienza di Torino

Also Known As

Marta Porebiak, P Racca, P. Racca, Patrizia Racca, Racca, P

124

Publications

5.3K

Citations

30

H-Index

39

Concepts

All Affiliations

Azienda Ospedaliera Citta' della Salute e della Scienza di TorinoUniversity of TurinIstituto Oncologico VenetoIstituti di Ricovero e Cura a Carattere ScientificoAzienda Ospedaliera Universitaria Pisana
PR

About

Patrizia Racca is an author at Azienda Ospedaliera Citta' della Salute e della Scienza di Torino specializing in medicine, oncology, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

16

19

3.2K

2

Health Sciences

7

7

361

3

Biostatistics

1

1

32

4

Cell Biology

1

1

1.1K

5

Gastroenterology

1

1

309

Patrizia Racca

×

43

Publications

4.8K

Citations

28

H-Index

YearCitations

Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients

Giulia Siravegna, Benedetta Mussolin, Michela Buscarino,

Nature Medicine

2015

1.1K

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial

Andrea Sartore‐Bianchi, Livio Trusolino, Cosimo Martino,

The Lancet Oncology

2016

984

Assessment of a HER2 scoring system for colorectal cancer: results from a validation study

Emanuele Valtorta, Cosimo Martino, Andrea Sartore‐Bianchi,

Modern Pathology

2015

309

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

Chiara Cremolini, Carlotta Antoniotti, Daniele Rossini,

The Lancet Oncology

2020

309

Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer

Ludovic Barault, Alessio Amatu, Giulia Siravegna,

Gut

2017

231

HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer

Andrea Sartore‐Bianchi, Alessio Amatu, Luca Porcu,

The Oncologist

2019

165

Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO

Emanuela Dell’Aquila, Chiara Cremolini, Tea Zeppola,

Annals of Oncology

2018

134

Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O<sup>6</sup>-Methylguanine–DNA Methyltransferase–Silenced Metastatic Colorectal Cancer: The MAYA Trial

Federica Morano, Alessandra Raimondi, Filippo Pagani,

Journal of Clinical Oncology

2022

120

Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO

Chiara Cremolini, Carlotta Antoniotti, Sara Lonardi,

Annals of Oncology

2018

104

Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With <i>RAS</i> Wild-Type Metastatic Colorectal Cancer

Filippo Pietrantonio, Federica Morano, Salvatore Corallo,

JAMA Oncology

2019

103

Page 1